Introduction {#s0005}
============

Breast Cancer (BC) is the second most common lethal malignancy in women and the leading cause of cancer-related death in women worldwide [@b0005]. It has been reported that over half (52%) of new BC cases and 62% of deaths occur in economically developing countries [@b0010]. In Egypt, BC is the most common cancer among females accounting for 37.7% of about 12,000--13,000 new cases per year. These estimates have been confirmed in many regional Egyptian cancer registries [@b0015], [@b0020].

Recently, the Next Generation Sequencing (NGS) technology has provided a fast and cost effective means to characterize the mutations in the individual patient genome, which shed light on the mutated cancer genes involved in cancer progression [@b0025]. NGS has been used to study the mutation pattern in BC patients from different ethnic groups and at different disease stages. In many studies, whole genome and whole exome sequencing have been used to study BC mutations on large number of patients [@b0030], [@b0035].

Further focused analysis using targeted sequencing was later conducted in many studies: Pereira et al. studied the somatic mutation profile conducted on 2433 patients using a custom gene panel of 173 genes and identified 40 mutation-driver genes [@b0040]. Meric-Bernstam et al. used panel of 182 genes and determined the spectrum of genomic alterations in primary and metastatic BC [@b0045]. Also, Wiesman et al. used a custom gene pane of 229 genes and identified the key somatic mutations previously reported in triple negative BC [@b0050]. Moreover, Smith et al. could detect clinically actionable mutations in BC solid tumors using the MammaSeq [@b0055]. On the other hand, Liu et al. and Bai et al. used Ion Torrent Ampliseq Cancer Panel to identify genetic mutations in BC tumors to help developing personalized treatment protocols or combination therapies [@b0060], [@b0065]. The previous studies covered mostly European and North American populations. Little is done to study the somatic profile for other ethnic groups; we could only locate the work on the Chinese [@b0070], [@b0075], Mexico and Vietnam [@b0080] populations. To great extent, these studies were successful in understanding the molecular basis of the disease. Therefore, it was necessary to conduct such targeted sequencing studies on the Egyptian population to answer an important question: how the Egyptian patients are different in terms of mutations and affected genes from other populations? Answering this question helps understanding the Egyptian BC profiling which will help in the future evaluating drug efficacy and treatment protocols for that population. So, we developed this cohort study to explore the landscape of somatic mutations in Egyptian BC patients. We used the Ion Torrent sequencing technology (Ion AmpliSeq Comprehensive Cancer Panel) to sequence 409 tumor suppressor genes and oncogenes from 46 BC tumors of various subtypes.

Patients and methods {#s0010}
====================

Ethics statement {#s0015}
----------------

All human subject protocols and procedures were approved by the Institutional Review Board (IRB number: IRB00004025) of National Cancer Institute (NCI), Cairo University, Egypt which conducted the study in accordance with ICH-GCP guidelines (approval number: MD2010014038.3). A written informed consent was obtained from each patient during the enrollment into this study.

Patient samples {#s0020}
---------------

Tissue samples used in this cohort were recruited from the Egyptian National Cancer Institute from October 2016 to March 2018. Forty-six fresh tissue samples from Egyptian BC female patients were collected at surgery. Included patients were naïve to treatment and those receiving neoadjuvant chemotherapy were excluded. Patients were classified according to age, histological type, histological grade, hormone receptor status (estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her2)) and molecular subtype (Luminal A, Luminal B, Her2- over-expressing and triple negative). All the clinico-pathological features of the studied patients were collected from the clinical records.

DNA preparation {#s0025}
---------------

Twenty-five mg of fresh tissues were collected from 46 BC female patients. DNA was isolated using QIAamp® DNA Mini Kit (Qiagen, Germany: Cat. No. 51304) following manufacturer's instructions. For each sample, the isolated DNA was quantified using Nanodrop 2000 Spectrophotometer (Thermo Fisher Scientific) and Qubit 4 Fluorometer (Thermo Fisher Scientific). Moreover, DNA was checked by electrophoresis using 2% Ethidium-Bromide-stained agarose gel and visualized under UV *trans*-illuminator to confirm its integrity.

Ion AmpliSeq™ DNA library preparation, template preparation and sequencing {#s0030}
--------------------------------------------------------------------------

Ion AmpliSeq™ DNA Library was constructed using the Ion AmpliSeq™ Library Kit 2.0 (Cat. No. 4480441) which is designed for preparation of amplicon libraries using Ion AmpliSeq Comprehensive Cancer panels (Ion AmpliSeq CCP, Life Technologies, Cat. no. 4477685). For this, four amplicon pools per sample covering the 409 genes were quantified by qPCR with the Ion Library Quantitation Kit (Life Technologies, Cat. no. 4468802). The concentration and size of the library were determined by Agilent 2100 BioAnalyzer and DNA High-Sensitivity Lab Chip (Agilent Technologies). The quality of the libraries was assessed by QIAxcel advanced (QIAGEN). Then, the quantified libraries were preceded to template preparation on the ion chef using the Ion PI Hi-Q Chef Kit (Life Technologies, Cat. No. A27198) and loaded into an Ion PI Chip (Life Technologies, Cat. No. A26770) to be sequenced on the Ion proton using the Ion Proton Sequencing 200 Kit v2 (Life Technologies, Cat. No. 4485149).

Variant calling and variant classification {#s0035}
------------------------------------------

The bioinformatics analysis pipeline started with checking the QC step where the reads of each NGS run were examined and low quality parts were trimmed out. We then ran the alignment of the reads to the human reference genome (version hg19). For that step, we used the Torrent Suite as recommended by the manufacturer. A run was accepted only if the total number of aligned reads covered at least 95% of the target regions with an average depth of coverage of 668X. After alignment, we ran the TSVC module of the Torrent Suite to call the variants, using the options for calling somatic variants with hotspots. The qualified variants were annotated using an in-house developed system composed of different databases: we used the ANNOVAR [@b0085] package to annotate the variants with all available public population information. For cancer Few variants databases, we used the Catalogue of Somatic Mutations in Cancer COSMIC [@b0090] and CIViC [@b0095]. The possible impact of amino acid changes was assessed with PolyPhen-2 [@b0100], Sift [@b0105], and CADD [@b0110] prediction tools to understand their potential role in carcinogenesis. The identified variants were classified as benign or pathogenic according to Clin Var database [@b0115]. For identifying somatic mutations and filtering out germline variants in the absence of normal tissues, we used the in silico methods of [@b0120], [@b0125] using our database sets. The filtration algorithm has the following steps: the variants with accepted quality, depth of coverage, and existence in our hotspot regions are retained for further analysis. Variants that exist in COSMIC database or those that exist in population databases (including our in-house one) with minimum allele frequency (MAF) less than 1% were retained. Variants that do not exist in cancer CiViC or COSMIC were filtered out. Finally, the remaining variants were inspected manually on IGV to revise their alignments and neighboring sequences.

Results {#s0040}
=======

In this cohort study, we sequenced 46 BC samples from Egyptian patients ranging from 29 to 73 years of age. Patients classification was based on their age, histological type, histological grade, receptor status (ER, PR, and Her-2 Neu), and molecular classification as shown in [Table 1](#t0005){ref-type="table"}. In this study, we used Ion AmpliSeq™ Comprehensive Cancer Panel which was designed to target 409 tumor suppressor genes and oncogenes across multiple gene families to identify somatic mutations among Egyptian BC patients and their frequencies.Table 1Clinical features of the studied 46 Egyptian patients.CharacteristicsNumberAge (Years)Mean: 54.75\
Median: 55\
Range: 29--77\<40 y540--50 y850--60 y18≥60 y15  HR statusER+33ER-13PR+27PR-19  GradeI3II33III10  Histological typeInvasive duct carcinoma41Invasive tubular carcinoma1Invasive micropapillary carcinoma1Invasive tubulolobular carcinoma2Invasive duct & Invasive lobular carcinoma (mixed)1  Molecular classificationLuminal A25Luminal B9Her2- enriched8Basal like (triple negative)4

Our analysis showed that there were 44 out of 46 patients had somatic mutations. Initial filtering yielded 79 variants. By looking up these variants in the most recent version of the COSMIC database (version 90), we found that 28 of them have been reclassified as SNP. Therefore, they were excluded from further discussion. This reclassification was due to their frequencies in the ExAC and GnomAD databases. From the remaining 51 variants, there were 10 benign ones according to Clinvar database with frequency higher than 1% in ExAC and GnomAD databases except for one variant (p.E168D) in *MET* gene. The final remaining set of somatic variants includes 38 variants; out of them there were 4 novel variants, as they did not show up in any of the public databases. Three of these novel variants (p.F151V, p.H263Q & p.T600I) were predicted to be damaging by CADD-phred and PolyPhen2 prediction tools.

We detected different somatic mutations (Substitution -- missense, Frame shift deletion, Substitution -- coding silent, Substitution -- nonsense, In Frame shift insertion, and Substitution- intronic). Summary of types and numbers of the detected somatic mutations is shown in [Fig. 1a](#f0005){ref-type="fig"}. Fifty one somatic mutations were detected in 22 genes, out of them there were: 19 pathogenic or likely pathogenic variants, 10 benign or likely benign variants, 5 variants of uncertain significance, 4 variants with conflicting interpretation of pathogenicity, 8 variants not reported in Clinvar database, 4 novel variants, an 1 drug response variant as shown in [Fig. 1b](#f0010){ref-type="fig"}. The distribution of somatic mutations in the studied BC patients was shown in the Oncoplot ([Fig. 2](#f0015){ref-type="fig"}**).** We also analyzed variants with Ingenuity Variant Analysis software (IVA; QIAGEN) for further variant annotation and interpretation. IVA showed that PI3K/AKT signaling was up- regulated in 54% of our patients as shown in [Fig. 3](#f0020){ref-type="fig"}a and [3b](#f0025){ref-type="fig"}.Fig. 1aSummary of types and numbers of the detected somatic mutations.Fig. 1bClassification of the identified variants.Fig. 2Oncoplot showing the distribution of somatic mutations in the studied breast cancer patients. The Oncoplot provided an overview of somatic mutations in particular genes (rows) affecting individual samples (columns). According to the logic of oncoplot, if a sample has more variants, it is counted once, and not with the total frequencies. The plot shows total positive 44 samples. The substitution mutations were shown in green, indels were shown in red.Fig. 3a. PI3K/AKT signaling pathway identified using ingenuity variant analysis (IVA). Blue represents loss of function, orange represents gain of function, and grey inferred normal.Fig. 3bPI3K/AKT signaling pathway identified using ingenuity variant analysis (IVA). Blue represents loss of function, orange represents gain of function, grey inferred normal, and entities outlined in red are potential drug targets.

Tumor protein TP53 (*TP53*), phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (*PIK3CA*), proto-oncogene c-Kit (*KIT*), Phosphatase and Tensin Homolog (*PTEN*), proto-oncogene MET (*MET*), and Kirsten Rat Sarcoma (*KRAS*) were the most common mutated genes (≥2 variants per gene). *TP53* was the most mutated one (15 different variants), followed by *PIK3CA* (8 different variants), *KIT* (3 variants), *PTEN* (2 variants), *KRAS* (2 variants), *TSC1* (2 variants) and *MET* (2 variants). The detailed list of the affected genes, incurred somatic mutations, mutation type, frequency, zygosity and other data are listed in [Table 2](#t0010){ref-type="table"}.Table 2Somatic mutations detected in 46 Egyptian BC patients:GeneFunctionAA mutationCDS mutationMutation typeSamples with mutationZygosityCADD Phred predictionHot spotClinvar*KIT*Exonic; splicingp.L862Lc.2586G \> CSubstitution -- coding silent10Het.----BenignExonic; splicingp.M541Lc.1621A \> CSubstitution -- Missense6Het.--4-55593464BenignExonic; splicingp.K546Kc.1638A \> GSubstitution -- coding silent5Het.--4-55593481Benign  *TSC1*Exonicp.F608Lfs\*21c.1824delFrame shift deletion12Hom.D--Not reportedExonicp.L203Cfs\*7c.608delFrame shift deletion2Hom.D--Not reported  *TSC2*Exonicp.F298Lfs\*65c.894delFrame shift deletion3Hom.D--Not reported*CEBPA*Exonicp.A176Vc.527C \> TSubstitution -- Missense7Het.D--Uncertain significance  *KRAS*Splicing--c.575-9G \> ASubstitution- Intronic6Het.----BenignExonicp.G12Vc.35G \> TSubstitution -- Missense1Het.D12-25398284Pathogenic  *PDGFRA*Exonic--c.2472C \> TSubstitution -- coding silent6Het.--4-55152040Benign  *PTEN*Exonicp.E288fsc.863delAFrame shift deletion6Hom.--10-89720712Not reported1Het.--Exonicp.R130Xc.388C \> TSubstitution -- Nonense (stopgain)1Het.D10-89692904Pathogenic  *VHL*Exonicp.F148fsc.440delTFrame shift deletion5Hom.--3-10188297Pathogenic*NOTCH4*Exonicp.K117Qc. 349A \> CSubstitution -- Missense4Hom.----Not reported*STK11*Exonicp.G279fsc.837delCFrame shift deletion4Het.--19-1221314PathogenicGeneFunctionAA mutationCDS mutationMutation typeSamples with mutationZygosityCADD Phred predictionHot spotClinvar*P53*Exonicp.R175Hc.524G\>ASubstitution -- Missense1Het.D17-7578406Pathogenicp.R282Wc.844C\>TSubstitution -- Missense1Het.D17-7577094Pathogenicp.C176Wc.528C\>GSubstitution -- Missense1Het.D17-7578402Uncertain significancep.Y234Cc.701A\>GSubstitution -- Missense1Het.D17-7577580Pathogenicp.R280Gc.838A\>GSubstitution -- Missense1Het.D17-7577100conflicting interpretations of pathogenicityP.G245Dc.734G\>ASubstitution -- Missense1Het.D17-7577547Pathogenicp.P72Ac.214C\>GSubstitution -- Missense4Het.--17-7579473Uncertain significancep.P72Rc.215C\>GSubstitution -- Missense8Hom.--17-7579472Drug responsep.C135fsc.403delTFrame shift deletion2Hom.--17-7578527Uncertain significance1Het.p.A276Pc.826G\>CSubstitution -- Missense1Het.D17-7577112conflicting interpretations of pathogenicityExonic; splicingp.Y220Cc.659A\>GSubstitution -- Missense1Het.D17-7578190Pathogenicp.Q331\*c.991C\>TSubstitution -- Nonense (stopgain)1Het.D--Not reportedp.K132Rc.395A\>GSubstitution -- Missense1Het.D17-7578535Uncertain significancep.R306\*c.916C\>TSubstitution --Nonense (stopgain)1Het.D17-7577022PathogenicSplicing--c.376-1G\>ASubstitution- Intronic1Het.D17-7578555PathogenicGeneFunctionAA mutationCDS mutationMutation typeSamples with mutationZygosityCADD Phred predictionHot spotClinvar*PIK3CA*Exonicp.H1047Rc.3140A\>GSubstitution -- Missense10Het.D3-178952085Pathogenicp.I391Mc.1173A\>GSubstitution -- Missense7Het.----Benignp.T1025Tc.3075C\>TSubstitution -- coding silent4Het.--3-178952020Benignp.E542Kc.1624G\>ASubstitution -- Missense1Hom.D3-178936082Pathogenic*With*p.E80Kc.238G\>ASubstitution -- Missense1Het.D3-178916851Not reportedp.Q546Rc.1637A\>GSubstitution -- Missense1Het.D3-178936095Pathogenicp.E545Kc.1633G\>ASubstitution -- Missense2Het.D3-178936091Pathogenicp.E365Kc.1093G\>ASubstitution -- Missense1Het.D--Pathogenic  *JAK3*Exonicp.V722Ic.2164G\>ASubstitution -- Missense2Het.D19-17945696conflicting interpretations of pathogenicity  *APC*Exonicp.G2502Sc.7504G\>ASubstitution -- Missense2Het.D--Benignp.E1317Qc.3949G\>CSubstitution -- Missense1Het.--5-112175240Conflicting interpretations of pathogenicity  *MET*Exonicp.N375Sc.1124A\>GSubstitution -- Missense1Het.--7-116340262Benignp.E168Dc.504G\>TSubstitution -- Missense1Het.--7-116339642BenignGeneFunctionAA mutationCDS mutationMutation typeSamples with mutationZygosityCADD Phred predictionHot spotClinvar*AKT1*Exonicp.E17Kc.49G\>ASubstitution -- Missense2Het.D14-105246551Pathogenic*MAP2K4*Exonic ; splicingp.Q80\*c.238C\>TSubstitution -- Nonense (stopgain)1Het.D--Not reported*IDH2*Exonicp.R140Qc.419G\>ASubstitution -- Missense1Het.D15-90631934Pathogenic*ERBB2*Exonicp.V777Lc.2329G\>TSubstitution -- Missense1Het.D17-37881000Pathogenic*EPHB1*Exonicp.F151Vc.451T\>GSubstitution -- Missense14Het.D--Novel*KIT*Exonicp.H263Qc.789T\>GSubstitution -- Missense10Het.D--Novel*MTOR*Exonic; splicingp.T600Ic.1799C\>TSubstitution -- Missense9Het.D--Novel*JAK2*Exonic--c.2041_2042delinsTAinframeshift substitution6Het.----Novel

Fifteen different somatic mutations were detected in TP53 gene; all, except only one, were within known hotspot regions and most of them were classified as pathogenic. Notably, one *TP53* drug response variant (p.P72R) was detected in 8 samples.

Eight different somatic mutations were detected in *PIK3CA* gene. p.H1047R, p.E545K, p.E542K, p.E80K, and p.Q546R were found at known hotspot regions and classified as pathogenic. p.H1047R is the most frequently detected pathogenic somatic mutation in this study. Another *PIK3CA* variant (p.I391M) was detected in 7 samples and one more *PIK3CA* substitution coding silent variant (p.T1025T) was detected in 4 samples.

Three different somatic mutations were detected in *KIT* gene; p.L862L, p.M541L, p.K546K in 9, 6, and 5 samples respectively. On the other hand, two different *PTEN* somatic mutations were detected; one variant (p.E288fs) in 6 samples as homozygous mutation and in one sample as heterozygous mutation and the other variant (p.R130X) in one sample. While *KRAS* gene had one substitution intronic splicing variant in 6 samples and 1 sample harbored one missense variant (p.G12V). Interestingly, we detected 2 frame shift deletions (p.F148fs and p.G279fs) in *VHL* and *STK11* genes in 5 and 4 samples, respectively. These two variants were recorded as pathogenic in NCBI Clin Var database. In addition, 3 frame shift deletions were detected; 2 (p.F608Lfs\*21 and p.L203Cfs\*7) in *TSC1* gene and 1 (p.F298Lfs\*65) in *TSC2* gene*.* Moreover, one substitution-intronic variant in platelet derived growth factor receptor alpha (PDGFRA) was detected in 6 samples and this variant is pathogenic according to FATHMM score.

Discussion {#s0045}
==========

The identification of somatic mutations analyzed by Next- Generation Sequencing is increasingly used in clinical research as it allows deepening the knowledge of cancer progression. In this work we used Ion AmpliSeq Comprehensive caner panel to target most frequently cited and mutated cancer related genes and to report the frequency of the detected somatic mutations among 46 Egyptian BC patients. To the best of our knowledge, this is the first Egyptian cohort to sequence a multiple-gene panel of cancer related genes on BC patients.

In this cohort, we detected somatic mutations in genes previously reported to be frequently mutated in BC: *TP53*, *PIK3C*A, *PTEN*, *AKT1*, and *MAP2K4*. In addition, other somatic mutations were detected in genes recently reported to be mutated in BC; *KRAS*, *PDGFRA, VHL*, *STK11*, *APC*, *MET*, *JAK3*, *SMARCB1*, *ERBB2*, and *IDH2* [@b0130]. Matching with several previous studies, *TP53* and *PIK3CA* were the most top two frequently mutated genes in BC proving their importance in carcinogenic process [@b0070]. On the contrary, we detected variants at a relatively high frequency in *STK11*, *KRAS*, and *ERBB2* genes, which were previously reported to occur infrequently in BC [@b0035], [@b0135].

*TP53* is a key transcription factor that participates in repair of DNA damage, cell cycle check point control, and apoptosis induction. *TP53* is mutated in BC in around 30--35% of cases and losing its normal functions causes tumorigenesis. In this cohort, 15 different *TP53* somatic mutations were present in 58.7% (27 out of 46) of patients and they were all (except one) within known hotspot regions. Of interest, two polymorphic variants of *TP53* gene were detected; the most frequent one was TP53 p.P72R (COSM250061) in 8 patients (17.4%) followed by TP53 p.P72A (COSM3738520) in 4 patients (8.7%). There are contradictory results about if *TP53* codon 72 polymorphism is associated with BC risk or not. In meta-analysis by Zhang et al., it was reported that TP53 P72R contributes to BC susceptibility [@b0140]. On the contrary, Ma et al. found that TP53 P72R showed no significant association with BC risk [@b0145]. This null significant association was verified again in updated meta-analysis by Cheng et al. [@b0150]. Therefore, an additional large study is required to validate this association in our Egyptian BC patients.

On the other hand, it was reported that *TP53* polymorphism may influence individual responsiveness to cancer chemotherapy via modulation of *TP73*-dependent apoptosis [@b0155]. The ability of mutant *TP53* to bind to *TP73*, the *TP53*-family member, and inactivate it is influenced by *TP53* codon 72 [@b0160]. Xu et al., indicated that BC patients with the Pro/Pro genotype were less sensitive to a neoadjuvant chemotherapy regimen that included 5-fluorouracil, cyclophosphamide, and the anthracycline-based neoadjuvant chemotherapy than those with the Arg/Arg or Arg/Pro genotypes [@b0165]. Similar results were reported in head and neck carcinoma \[sullivan 2004\]. It was also reported that Arg/Arg genotype induces apoptosis more effectively than Pro/Pro genotype, which may be due to enhanced mitochondrial localization of *TP53* protein in cells with the Arg/Arg genotype [@b0170]. Furthermore, it was reported that mutant *TP53* with the R72 variant was significantly associated with poor prognosis in women with BC [@b0175]. Thus, it is suggested that *TP53* codon 72 might be a strong predictive marker for chemotherapy response in BC patients.

Genetic alteration causes abnormalities in PI3K/AKT/mTOR pathway and results in deregulated kinase activity and malignant transformation. Thus, target therapies are being actively investigated to inhibit this pathway including; PI3K inhibitors such as pictilisib, alpelisib, copanlisib, and taselisib; AKT inhibitors such as ipatasertib; and mTOR inhibitors such as everolimus [@b0180]. *PIK3CA* gene is an important component of the phosphoinositide-3 kinase (PI3K) pathway which is frequently altered in human cancers. Deregulation of the PI3K pathway, through the acquired somatic mutations, contributes to tumors development and progression. In The Cancer Genome Atlas (TCGA) and COSMIC databases, it was reported that *PIK3CA* gene is mutated in \~36% of BC [@b0185]. In patients with *PIK3CA* mutations, recent study showed promising results in progression‐free survival when using buparlisib, PI3K inhibitor; in combination with endocrine therapy [@b0190]. Many other studies revealed that patients with *PIK3CA* mutations might benefit from PI3K‐selective inhibitor treatment [@b0195], [@b0200]. On the other hand, *AKT* gene is the PI3K effector and AKT signalling leads to increased cellular growth and survival. A somatic mutation (E17K) in *AKT*1 gene was discovered in 8% of BC [@b0205]. At least one component of PI3K/AKT/mTOR pathway is altered in more than 50% of ER/PR positive tumors, and these alterations cause tumor growth and develop resistance to antihormone therapies. Thus, hormone receptor positive tumors will benefit from using PI3K/AKT inhibitors in combination with endocrine therapy [@b0210]. We detected eight different *PIK3CA* mutations in 27 patients (58.7%). H1047R, E545K, E542K, Q546R, p.E80K hotspots accounted for 55.6% of all *PIK3CA* mutations in our cohort. We also detected *PIK3CA* I391M polymorphism; which is far from the binding site but can affect the protein function and change its dynamic action. It was suggested by Ahmadi et al. that this polymorphism may be involved in BC invasion [@b0215]. This variant was present in 7 patients (15.2%) and may be used as marker for BC tumorigenesis. Another remaining *PIK3CA* (p.T1025T) polymorphism in our cohort is thought to be Arab specific variant. This SNP rs17849079 (p.T1025T) was reported at high prevalence among Arab BC patients and suggested to be used as a molecular marker for early diagnosis in this population [@b0220]. So, further studies are needed to validate the use of such structural variants as SNP marker for BC early detection and invasion. Moreover, we found one hotspot mutation in *AKT1* gene (exon3:c.49G \> A: p.E17K) in two patients of luminal A and Triple negative subtypes. It was reported that BC patients with AKT p.E17K mutation are sensitive to AKT inhibitors [@b0225]. Thus Egyptian BC patients carrying this mutation may represent good candidates for AKT inhibitors treatment. In this study and according to IVA, we identified many mutated genes that commonly up-regulate PI3K/AKT signaling pathway and promote carcinogenesis. Thus, we propose that Egyptian BC patients might benefit from PI3K/AKT inhibitors in combination with endocrine therapy.

Two pathogenic frame shift deletion variants in *VHL* and *STK11* were detected in 5 and 4 samples, respectively. Other two frame shift deletion variants in *TP53* and *PTEN* were identified. Interestingly, 2 patients were found to concomitantly harbor these four frame shift variants. This combination of mutation may contribute the BC development in those patients.

Loss of *PTEN* function, on basis of somatic mutations, mostly affects tumor development across tissues. In the nucleus, *PTEN* promotes chromosome stability and DNA repair. Consequently, loss of *PTEN* function increases genomic instability [@b0230]. Also, improper *PTEN* function leads to uncontrolled activation of its downstream signals. One frame shift deletion and one stop gain variants in *PTEN* gene were identified. A deletion in codon 288, exon 8 of *PTEN*, resulting in a frame shift mutation (p.E288fs) was detected in 7 samples of Luminal A subtype. The stop gain variant (p.R130X) was detected in one sample which was stage I. A combination mutation in *PIK3CA* (p.H1047R) and *PTEN* (p.R130X) was also identified.

In addition, we identified rare hotspot point mutation in KRAS (exon2:c.35G \> T: p.G12V) that have been previously reported in ductal carcinomas [@b0235]. In our sample set, this mutation was found in one case co-occurred with another PIK3CA point mutation (p.T1025T) in luminal B (Her2+) subtype. This might explain the contribution of this co-occurrence in BC susceptibility as a driver mutation in tumor development. Furthermore, we identified an important pathogenic *ERBB2* variant (p.V777L). In a study by Cocco et al, it was proposed that Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 [@b0240].

In conclusion NGS is a very useful tool to evaluate the mutational status of oncogenes and tumor suppressor genes to help identify the mutation drivers of BC [@b0245]. In this cohort we shed the light on the most frequently detected somatic mutations and most altered pathways in Egyptian BC patients.

Recommendation {#s0050}
==============

We recommend following up the patients until diagnosis of recurrence or metastasis and following up their response to treatment to give more focus on the association between survival data and the identified somatic mutations which may have important clinical implications for personalized medicine, target therapy, therapeutic guidance, and monitoring of recurrence or metastasis. Moreover, we recommend sequencing the most frequently detected genes from this preliminary study to confirm our findings on large number of BC patients. In addition, giving more focus on triple negative BC patients as it is the most aggressive and has a poor prognosis.
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